Preserved Bimatoprost 0.01% — Competitive Intelligence Brief

Preserved Bimatoprost 0.01% (Preserved Bimatoprost 0.01%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Prostaglandin F analog. Area: Ophthalmology.

marketed Prostaglandin F analog Prostaglandin F receptor (FP receptor) Ophthalmology Small molecule

Target snapshot

Preserved Bimatoprost 0.01% (Preserved Bimatoprost 0.01%) — Universitaire Ziekenhuizen KU Leuven. Bimatoprost is a prostaglandin F analog that increases uveoscleral outflow of aqueous humor to reduce intraocular pressure.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Preserved Bimatoprost 0.01% TARGET	Preserved Bimatoprost 0.01%	Universitaire Ziekenhuizen KU Leuven	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
travatan 0.004%	travatan 0.004%	Allergan	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
travoprost 0.004% (drug)	travoprost 0.004% (drug)	University Hospital, Basel, Switzerland	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
Preservative-free bimatoprost	Preservative-free bimatoprost	Association for Innovation and Biomedical Research on Light and Image	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
Generic travoprost	Generic travoprost	Université de Sherbrooke	marketed	Prostaglandin F analog	Prostaglandin F (FP) receptor
Topical latanoprost 0.005%	Topical latanoprost 0.005%	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)
preservative free tafluprost 0.0015%	preservative free tafluprost 0.0015%	Tun Hussein Onn National Eye Hospital	marketed	Prostaglandin F analog	Prostaglandin F receptor (FP receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Prostaglandin F analog class)

1. Allergan · 8 drugs in this class
2. CHU de Quebec-Universite Laval · 2 drugs in this class
3. Association for Innovation and Biomedical Research on Light and Image · 2 drugs in this class
4. Kasr El Aini Hospital · 1 drug in this class
5. Merck Sharp & Dohme LLC · 1 drug in this class
6. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
7. Post Graduate Institute of Medical Education and Research, Chandigarh · 1 drug in this class
8. SpyGlass Pharma, Inc. · 1 drug in this class
9. Tun Hussein Onn National Eye Hospital · 1 drug in this class
10. Universitaire Ziekenhuizen KU Leuven · 1 drug in this class